PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33156411-0	2021	Erythropoietin-stimulating agent-resistant vitamin B6 deficiency anemia in a pediatric patient on hemodialysis.	Vitamin B 6	43-53	erythropoietin	Homo sapiens	0-14	
21609363-13	2011	Advances in renal medicine including the use of erythropoietin stimulating agents and ion exchange phosphate binding resins were shown to negatively affect vitamin B6 status.	Vitamin B 6	156-166	erythropoietin	Homo sapiens	48-62	
10645030-12	1999	Erythrocyte vitamin B6 and folic acid significantly decreased due to erythropoietin treatment.	Vitamin B 6	12-22	erythropoietin	Homo sapiens	69-83	
10334668-9	1999	Vitamin B6 requirements are increased during epoetin therapy, and supplementation at a dose of 100-150 mg/week is recommended.	Vitamin B 6	0-10	erythropoietin	Homo sapiens	45-52	
10978399-0	2000	Vitamin B6 supplementation can improve peripheral polyneuropathy in patients with chronic renal failure on high-flux haemodialysis and human recombinant erythropoietin.	Vitamin B 6	0-10	erythropoietin	Homo sapiens	153-167	
9350682-9	1997	Indirect evidence has shown that erythrocyte vitamin B6 is consumed by the hemoglobin synthesis much more during EPO treatment in hemodialysis patients.	Vitamin B 6	45-55	erythropoietin	Homo sapiens	113-116